U118MG tumors were also harvested at 30 days post-RIT treatment (at tumor volume nadir) to enable us to investigate the earlier effects of LRRC15-RIT, while the later time point provided insight into the transcriptome of the remaining tumor tissue, which often contributes to resistance and recurrence in patient settings. This evidence concerns the gene LRRC15 and neoplasm.